Human umbilical cord blood derived mesenchymal stem cells improve cardiac function in cTnTR141W transgenic mouse of dilated cardiomyopathy

European Journal of Cell Biology

Volumn 95, Issue 1, 2016, Pages 57-67

  Gong, Xuhe ^a   Wang, Pengbo ^a   Wu, Qingqing ^b   Wang, Sijia ^a   Yu, Litian ^a   Wang, Guogan ^a,b  

^a FUWAI HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Dilated cardiomyopathy; Paracrine effects; Umbilical cord blood mesenchymal stem cells

Indexed keywords

CELL SURFACE MARKER; GROWTH FACTOR; PROTEIN KINASE B; SOMATOMEDIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL STRUCTURE; CELL VACUOLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CYTOPLASM; FIBROSIS; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; HYPERTROPHY; HYPOXIA; IN VITRO STUDY; INFLAMMATION; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; TISSUE REGENERATION; TRANSGENIC MOUSE; UMBILICAL CORD BLOOD; UPREGULATION; ANIMAL; CARDIOMYOPATHY, DILATED; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE MODEL; MESENCHYMAL STEM CELL TRANSPLANTATION; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARDIOMYOPATHY, DILATED; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; HETEROGRAFTS; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84983102531     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2015.11.003     Document Type: Article

References (48)

1. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis?. Nat. Med. 2000, 6:1102-1103.
2. Chang C.P., Chio C.C., Cheong C.U., Chao C.M., Cheng B.C., Lin M.T. Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. Clin. Sci. 2013, 124:165-176.
3. Chen L., Xu Y., Zhao J., Zhang Z., Yang R., Xie J., Liu X., Qi S. Conditioned medium from hypoxic bone marrow-derived mesenchymal stem cells enhances wound healing in mice. PLoS ONE 2014, 9:e96161.
4. Clark D.J., Cleman M.W., Pfau S.E., Rollins S.A., Ramahi T.M., Mayer C., Caulin-Glaser T., Daher E., Kosiborod M., Bell L., Setaro J.F. Serum complement activation in congestive heart failure. Am. Heart J. 2001, 141:684-690.
5. Cui B., Li E., Yang B., Wang B. Human umbilical cord blood-derived mesenchymal stem cell transplantation for the treatment of spinal cord injury. Exp. Ther. Med. 2014, 7:1233-1236.
6. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
7. Franke T.F., Kaplan D.R., Cantley L.C. PI3 K: downstream AKTion blocks apoptosis. Cell 1997, 88:435-437.
8. Gulati A., Jabbour A., Ismail T.F., Guha K., Khwaja J., Raza S., Morarji K., Brown T.D., Ismail N.A., Dweck M.R., Di Pietro E., Roughton M., Wage R., Daryani Y., O'Hanlon R., Sheppard M.N., Alpendurada F., Lyon A.R., Cook S.A., Cowie M.R., Assomull R.G., Pennell D.J., Prasad S.K. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 2013, 309:896-908. (the journal of the American Medical Association).
9. Haneef K., Naeem N., Khan I., Iqbal H., Kabir N., Jamall S., Zahid M., Salim A. Conditioned medium enhances the fusion capability of rat bone marrow mesenchymal stem cells and cardiomyocytes. Mol. Biol. Rep. 2014, 41:3099-3112.
10. Hwang H.J., Chang W., Song B.W., Song H., Cha M.J., Kim I.K., Lim S., Choi E.J., Ham O., Lee S.Y., Shim J., Joung B., Pak H.N., Kim S.S., Choi B.R., Jang Y., Lee M.H., Hwang K.C. Antiarrhythmic potential of mesenchymal stem cell is modulated by hypoxic environment. J. Am. Coll. Cardiol. 2012, 60:1698-1706.
11. Jang H.R., Park J.H., Kwon G.Y., Lee J.E., Huh W., Jin H.J., Choi S.J., Oh W., Oh H.Y., Kim Y.G. Effect of preemptive treatment with human umbilical cord blood-derived mesenchymal stem cells on the development of renal ischemia-reperfusion injury in mice. Am. J. Physiol. Renal Physiol. 2008, 128(1):83-90.
12. Jefferies J.L., Towbin J.A. Dilated cardiomyopathy. Lancet 2010, 375:752-762.
13. Jin H.J., Bae Y.K., Kim M., Kwon S.J., Jeon H.B., Choi S.J., Kim S.W., Yang Y.S., Oh W., Chang J.W. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int. J. Mol. Sci. 2013, 14:17986-18001.
14. Juan F., Wei D., Xiongzhi Q., Ran D., Chunmei M., Lan H., Chuan Q., Lianfeng Z. The changes of the cardiac structure and function in cTnTR141W transgenic mice. Int. J. Cardiol. 2008, 128:83-90.
15. Koudstaal S., Bastings M.M., Feyen D.A., Waring C.D., van Slochteren F.J., Dankers P.Y., Torella D., Sluijter J.P., Nadal-Ginard B., Doevendans P.A., Ellison G.M., Chamuleau S.A. Sustained delivery of insulin-like growth factor-1/hepatocyte growth factor stimulates endogenous cardiac repair in the chronic infarcted pig heart. J. Cardiovasc. Transl. Res. 2014, 7:232-241.
16. Lee M., Jeong S.Y., Ha J., Kim M., Jin H.J., Kwon S.J., Chang J.W., Choi S.J., Oh W., Yang Y.S., Kim J.S., Jeon H.B. Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 2014, 446:983-989.
17. Li W., Ma N., Ong L.L., Nesselmann C., Klopsch C., Ladilov Y., Furlani D., Piechaczek C., Moebius J.M., Lutzow K., Lendlein A., Stamm C., Li R.K., Steinhoff G. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 2007, 25:2118-2127.
18. Mangi A.A., Noiseux N., Kong D., He H., Rezvani M., Ingwall J.S., Dzau V.J. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med. 2003, 9:1195-1201.
19. Martin-Rendon E., Brunskill S.J., Hyde C.J., Stanworth S.J., Mathur A., Watt S.M. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur. Heart J. 2008, 29:1807-1818.
20. Mendall M.A., Strachan D.P., Butland B.K., Ballam L., Morris J., Sweetnam P.M., Elwood P.C. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur. Heart J. 2000, 21:1584-1590.
21. Moon H.H., Joo M.K., Mok H., Lee M., Hwang K.C., Kim S.W., Jeong J.H., Choi D., Kim S.H. MSC-based VEGF, gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine. Biomaterials 2014, 35:1744-1754.
22. Mu Y., Cao G., Zeng Q., Li Y. Transplantation of induced bone marrow mesenchymal stem cells improves the cardiac function of rabbits with dilated cardiomyopathy via upregulation of vascular endothelial growth factor and its receptors. Exp. Biol. Med. (Maywood, NJ) 2011, 236:1100-1107.
23. Oran B., Shpall E. Umbilical cord blood transplantation: a maturing technology. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program 2012 2012, 215-222.
24. Perea-Gil I., Monguio-Tortajada M., Galvez-Monton C., Bayes-Genis A., Borras F.E., Roura S. Preclinical evaluation of the immunomodulatory properties of cardiac adipose tissue progenitor cells using umbilical cord blood mesenchymal stem cells: a direct comparative study. BioMed Res. Int. 2015, 2015:439808.
25. Phuc P.V., Nhung T.H., Loan D.T., Chung D.C., Ngoc P.K. Differentiating of banked human umbilical cord blood-derived mesenchymal stem cells into insulin-secreting cells. In vitro Cell. Dev. Biol. Anim. 2011, 47:54-63.
26. Prockop D.J., Oh J.Y. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol. Ther. 2012, 20:14-20. (the journal of the American Society of Gene Therapy).
27. Psaltis P.J., Zannettino A.C., Worthley S.G., Gronthos S. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 2008, 26:2201-2210.
28. Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., Olsen E., Thiene G., Goodwin J., Gyarfas I., Martin I., Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996, 93:841-842.
29. Roura S., Bago J.R., Soler-Botija C., Pujal J.M., Galvez-Monton C., Prat-Vidal C., Llucia-Valldeperas A., Blanco J., Bayes-Genis A. Human umbilical cord blood-derived mesenchymal stem cells promote vascular growth in vivo. PLoS ONE 2012, 7:e49447.
30. Roura S., Bayes-Genis A. Vascular dysfunction in idiopathic dilated cardiomyopathy. Nat. Rev. Cardiol. 2009, 6:590-598.
31. Roura S., Soler-Botija C., Bago J.R., Llucia-Valldeperas A., Fernandez M.A., Galvez-Monton C., Prat-Vidal C., Perea-Gil I., Blanco J., Bayes-Genis A. Postinfarction functional recovery driven by a three-dimensional engineered fibrin patch composed of human umbilical cord blood-derived mesenchymal stem cells. Stem Cells Transl. Med. 2015, 4:956-966.
32. Seitz W.S., Spiel M.S. Echocardiographic formula for computation of left ventricular volume and stroke volume. Comparison with cardiac catheterization and the Teichholz formula. Jpn. Heart J. 1983, 24:863-869.
33. Sesso H.D., Buring J.E., Rifai N., Blake G.J., Gaziano J.M., Ridker P.M. C-reactive protein and the risk of developing hypertension. JAMA 2003, 290:2945-2951. (the journal of the American Medical Association).
34. Seth S., Narang R., Bhargava B., Ray R., Mohanty S., Gulati G., Kumar L., Reddy K.S., Venugopal P., Group ACSCS. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial. J. Am. Coll. Cardiol. 2006, 48:2350-2351.
35. Singla D.K., Ahmed A., Singla R., Yan B. Embryonic stem cells improve cardiac function in Doxorubicin-induced cardiomyopathy mediated through multiple mechanisms. Cell Transpl. 2012, 21:1919-1930.
36. Sussman M.A., Volkers M., Fischer K., Bailey B., Cottage C.T., Din S., Gude N., Avitabile D., Alvarez R., Sundararaman B., Quijada P., Mason M., Konstandin M.H., Malhowski A., Cheng Z., Khan M., McGregor M. Myocardial AKT: the omnipresent nexus. Physiol. Rev. 2011, 91:1023-1070.
37. Takemura G., Kanoh M., Minatoguchi S., Fujiwara H. Cardiomyocyte apoptosis in the failing heart-a critical review from definition and classification of cell death. Int. J. Cardiol. 2013, 167:2373-2386.
38. Troncoso R., Ibarra C., Vicencio J.M., Jaimovich E., Lavandero S. New insights into IGF-1 signaling in the heart. Trends Endocrinol. Metab.: TEM 2014, 25:128-137.
39. Tucka J., Bennett M., Littlewood T. Cell death and survival signalling in the cardiovascular system. Front. Biosci. (Landmark edition) 2012, 17:248-261.
40. Vrtovec B., Poglajen G., Lezaic L., Sever M., Domanovic D., Cernelc P., Socan A., Schrepfer S., Torre-Amione G., Haddad F., Wu J.C. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ. Res. 2013, 112:165-173.
41. Walsh K. Akt signaling and growth of the heart. Circulation 2006, 113:2032-2034.
42. Wisel S., Khan M., Kuppusamy M.L., Mohan I.K., Chacko S.M., Rivera B.K., Sun B.C., Hideg K., Kuppusamy P. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J. Pharmacol. Exp. Ther. 2009, 329:543-550.
43. Yannarelli G., Dayan V., Pacienza N., Lee C.J., Medin J., Keating A. Human umbilical cord perivascular cells exhibit enhanced cardiomyocyte reprogramming and cardiac function after experimental acute myocardial infarction. Cell Transpl. 2013, 22:1651-1666.
44. Yaoita H., Maruyama Y. Intervention for apoptosis in cardiomyopathy. Heart Fail. Rev. 2008, 13:181-191.
45. Yoon C.H., Koyanagi M., Iekushi K., Seeger F., Urbich C., Zeiher A.M., Dimmeler S. Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardiovascular lineage commitment. Circulation 2010, 121:2001-2011.
46. Zhang Z., Li S., Cui M., Gao X., Sun D., Qin X., Narsinh K., Li C., Jia H., Li C., Han Y., Wang H., Cao F. Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways. Basic Res. Cardiol. 2013, 108:333.
47. Zhu Y., Guan Y.M., Huang H.L., Wang Q.S. Human umbilical cord blood mesenchymal stem cell transplantation suppresses inflammatory responses and neuronal apoptosis during early stage of focal cerebral ischemia in rabbits. Acta Pharmacol. Sin. 2014, 35:585-591.
48. Zlatkovic-Lindor J., Arrell D.K., Yamada S., Nelson T.J., Terzic A. ATP-sensitive K(+) channel-deficient dilated cardiomyopathy proteome remodeled by embryonic stem cell therapy. Stem Cells 2010, 28:1355-1367.